Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-18T02:15:13.309Z Has data issue: false hasContentIssue false

Chapter 17 - Optical coherence tomography in neurologic clinical trials

Published online by Cambridge University Press:  05 May 2015

By
Robert A. Bermel  and
Peter K. Kaiser
Edited by
Peter A. Calabresi ,
Laura J. Balcer  and
Elliot M. Frohman
Peter A. Calabresi
Affiliation:
Department of Neurology, Johns Hopkins University Hospital, Baltimore
Laura J. Balcer
Affiliation:
Department of Neurology, NYU Langone Medical Center, New York
Elliot M. Frohman
Affiliation:
Department of Neurology, UT Southwestern Medical Center, Dallas
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Optical Coherence Tomography in Neurologic Diseases , pp. 191 - 197
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Balcer, LJ, Baier, ML, Cohen, JA, Kooijmans, MF, Sandrock, AW, Nano-Schiavi, ML, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003; 61:1367–1373.CrossRefGoogle ScholarPubMed
Frohman, EM, Costello, F, Stuve, O, Calabresi, P, Miller, DH, Hickman, SJ, et al. Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. Arch Neurol 2008; 65:26–35.CrossRefGoogle ScholarPubMed
Cettomai, D, Pulicken, M, Gordon-Lipkin, E, Salter, A, Frohman, TC, Conger, A, et al. Reproducibility of optical coherence tomography in multiple sclerosis. Arch Neurol 2008; 65:1218–1222.CrossRefGoogle ScholarPubMed
Syc, SB, Warner, CV, Hiremath, GS, Farrell, SK, Ratchford, JN, Conger, A, et al. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler 2010; 16:829–839.CrossRefGoogle ScholarPubMed
Costello, F, Coupland, S, Hodge, W, Lorello, GR, Koroluk, J, Pan, YI, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59:963–969.CrossRefGoogle ScholarPubMed
Ratchford, JN, Saidha, S, Sotirchos, ES, Oh, JA, Seigo, MA, Eckstein, C, et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology 2013; 80:47–54.CrossRefGoogle ScholarPubMed
Multiple Sclerosis Standards – NINDS Common Data Elements.; 2014.Google Scholar
Bermel, RA, Fisher, E, Cohen, JA. The use of MR imaging as an outcome measure in multiple sclerosis clinical trials. Neuroimaging Clin N Am 2008; 18:687–701, xi.CrossRefGoogle ScholarPubMed
Warner, CV, Syc, SB, Stankiewicz, AM, Hiremath, G, Farrell, SK, Crainiceanu, CM, et al. The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. PLoS One 2011; 6:e22947.CrossRefGoogle ScholarPubMed
Henderson, APD, Altmann, DR, Trip, AS, Kallis, C, Jones, SJ, Schlottmann, PG, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010; 133:2592–2602.CrossRefGoogle ScholarPubMed
Talman, LS, Bisker, ER, Sackel, DJ, Long, DA,Jr, Galetta, KM, Ratchford, JN, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 2010; 67:749–760.CrossRefGoogle ScholarPubMed
Costello, F, Hodge, W, Pan, YI, Eggenberger, E, Freedman, MS. Using retinal architecture to help characterize multiple sclerosis patients. Can J Ophthalmol 2010; 45:520–526.CrossRefGoogle ScholarPubMed
Keltner, JL, Cello, KE, Balcer, LJ, Calabresi, PA, Markowitz, CE, Werner, JS. Stratus OCT Quality Control in Two Multi-Centre Multiple Sclerosis Clinical Trials. Neuro-Ophthalmology 2011; 35:57–64.CrossRefGoogle ScholarPubMed
Sakai, RE, Feller, DJ, Galetta, KM, Galetta, SL, Balcer, LJ. Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol 2011; 31:362–373.CrossRefGoogle ScholarPubMed
Winges, KM, Werner, JS, Harvey, DJ, Cello, KE, Durbin, MK, Balcer, LJ, et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American Phase 3 Fingolimod Trial for Relapsing-Remitting Multiple Sclerosis. Journal of Neuro-Ophthalmology 2013; 33: 322–329 10.1097/WNO.0b013e31829c51f7.CrossRefGoogle ScholarPubMed
OCTAGON trial. http://clinicaltrials.gov/ct2/show/results/NCT00856635; Accessed 12/2013.Google Scholar
Suhs, KW, Hein, K, Sattler, MB, Gorlitz, A, Ciupka, C, Scholz, K, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012; 72:199–210.CrossRefGoogle ScholarPubMed
Treatment of Optic Neuritis With Erythropoietin (TONE). http://clinicaltrials.gov/ct2/show/results/NCT00856635; Accessed 01/2014.Google Scholar
Esfahani, MR, Harandi, ZA, Movasat, M, Nikdel, M, Adelpour, M, Momeni, A, et al. Memantine for axonal loss of optic neuritis. Graefes Arch Clin Exp Ophthalmol 2012; 250:863–869.CrossRefGoogle ScholarPubMed
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis. http://clinicaltrials.gov/show/NCT01982942; Accessed 12/2013.Google Scholar
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial. http://clinicaltrials.gov/show/NCT01910259; Accessed 01/2014.Google Scholar
Neuroprotection with phenytoin in optic neuritis. http://clinicaltrials.gov/show/NCT01451593; Accessed 12/2013.Google Scholar
Amiloride clinical trial in optic neuritis. http://www.clinicaltrials.gov/show/NCT01802489; Accessed 12/2013.Google Scholar
Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON). http://www.clinicaltrials.gov/show/NCT01802489; Accessed 01/2014.Google Scholar
215ON201 BIIB033 In Acute Optic Neuritis (AON) (RENEW). http://clinicaltrials.gov/show/NCT01721161; Accessed 01/2014.Google Scholar
Connick, P, Kolappan, M, Crawley, C, Webber, DJ, Patani, R, Michell, AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11:150–156.CrossRefGoogle ScholarPubMed
Waubant, E. A phase II trial of neuroprotection with riluzole in early relapsing-remitting MS. ECTRIMS 2013, Copenhagen, Denmark. Late Breaking News Session 10/05/2013.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×